secwatch.observer — SEC 8-K summary
======================================

Issuer:     aTYR PHARMA INC (ATYR)
CIK:        0001339970
Form:       8-K
Filed at:   2024-08-13T23:59:59+00:00
Accession:  0000950170-24-096139
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

aTyr Pharma completes Phase 3 sarcoidosis trial enrollment; Q2 cash $81.4M
--------------------------------------------------------------------------

- Phase 3 EFZO-FIT study of efzofitimod in pulmonary sarcoidosis enrolled 268 patients; topline data expected Q3 2025.
- Cash, equivalents, restricted cash and investments totaled $81.4M as of June 30, 2024.
- R&D expenses $14.0M, G&A $3.3M for Q2 2024.
- Phase 2 EFZO-CONNECT for SSc-ILD enrolling; interim data expected Q2 2025.
- Appointed Jayant Aphale VP Technical Operations; research agreement with Stanford for anti-NRP2 in GBM.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1339970/000095017024096139/0000950170-24-096139-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1339970/000095017024096139/atyr-20240813.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-096139

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer